LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.Headache入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40583813PMC12916460 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.Clin Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40669578无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial.J Crit CarePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40845766无 PMCID | 2026-Feb | 0.85 | The study is a randomized controlled trial of drug interventions in human sepsis patients, but it is not an oncology study. The primary endpoint is 28-day mortality, which is a binary outcome, not a time-to-event endpoint such as overall survival or progression-free survival with time-to-event analysis. | 无 KM 图 |
| A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Azilsartan Medoxomil and Amlodipine Combination Therapy in Patients With Mild-to-Moderate Essential Hypertension Inadequately Controlled on Monotherapy.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40945998无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Minimally Invasive Surgery on Midline Shift and Outcomes in Large Supratentorial Spontaneous Intracerebral Hemorrhage: Post Hoc Analysis of MISTIE III.Neurocrit CarePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40958054无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women.Br J Clin Pharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40974130无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making.Value Health入排复审未纳入:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | PMID 41005700无 PMCID | 2026-Feb | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial.Osteoarthritis Cartilage疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41015076无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.Eur J Nucl Med Mol Imaging疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:非 KM 图;Fig. 3:非 KM 图。 | PMID 41032077PMC12860749 | 2026-Feb | 0.95 | The report is from a randomized Phase III trial in multiple myeloma with a drug intervention and presents original results. However, it does not include a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The outcomes are imaging validation metrics (CT values, SUV, MTV, TLG) and correlation analyses. Therefore, it is not eligible for inclusion in a Kaplan-Meier digitization cohort. | 无 KM 图 |
| A phase III clinical trial of monthly minodronate in the treatment of Chinese postmenopausal women with osteoporosis.Acta Pharmacol SinPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41034401PMC12811239 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study.ProstatePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41098072无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Overall survival with abemaciclib in early breast cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41110697无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41110701无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.Ann OncolAI 判定该论文不进入自动 KM 提取:The study is explicitly described as a phase I/II trial (KEYMAKER-U03 substudy 03A), not a phase III trial. | PMID 41115468PMC13335667 | 2026-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41115469无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41125211无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41130363无 PMCID | 2026-Feb | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).Clin Auton Res已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:ROC 图。 | PMID 41134458PMC12982295 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671.Ann Thorac Surg疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41203001无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.Diabetes Obes Metab疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:非 KM 图。 | PMID 41216778PMC12803687 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial.Addict BehavPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41237599PMC12751120 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthma.J Allergy Clin ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41242639无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41253648无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial.United European Gastroenterol J疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:ROC 图;FIGURE 3:AI 判定为 other。 | PMID 41284133PMC12811999 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.Diabetes Obes Metab疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。 | PMID 41290555PMC12803658 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图。 | PMID 41328546PMC12822771 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.J Prev Alzheimers Dis | PMID 41330788PMC12869028 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41354044无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.Nat Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:ROC 图;Fig. 3:ROC 图;Fig. 4:森林图/亚组分析图。 | PMID 41360993PMC12920101 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.Hypertension已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:研究设计图;Figure 3:研究设计图;Figure 4:森林图/亚组分析图。 | PMID 41363010PMC12822777 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.Neurourol Urodyn疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图。 | PMID 41363221PMC12893031 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.J Eur Acad Dermatol Venereol已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 41369155PMC12843872 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41389860无 PMCID | 2026-Feb | 0.90 | The record describes a randomized, Phase III trial with a time-to-event efficacy endpoint (OS, etc. are implied in the original trial, but this specific report focuses on morbidity). However, the intervention is radiotherapy, which is a non-drug intervention. The requirement is for a 'drug-containing intervention'. Therefore, it is excluded. | 无 KM 图 |
| Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.Tumori疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41392465无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41406403无 PMCID | 2026-Feb | 0.95 | The trial is a phase III randomized oncology trial with original results, but it is ineligible because the primary endpoint is an infection rate (non-time-to-event) and the intervention is a dietary comparison, not a drug-containing intervention. | 无 KM 图 |
| TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.Eye (Lond)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图。 | PMID 41413355PMC12881385 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.Adv Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:AI 判定为 flow diagram;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 2 张未列出。 | PMID 41442024PMC12909358 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of low-sodium oxybate on diary-based sleep time in a clinical study in adults with idiopathic hypersomnia.Sleep MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41442817无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.Adv Ther已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 forest plot。 | PMID 41461999PMC12909322 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Post-operative pain after laparoscopy in gynecologic surgery: randomized trial on peritoneal gas drainage.Int J Gynecol CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41485402无 PMCID | 2026-Feb | 0.85 | While this is a Phase III RCT conducted in an oncology setting (gynecologic surgery at a cancer center), it is not an oncology efficacy trial. The primary and secondary outcomes are post-operative pain and analgesic use, not survival, progression, recurrence, death, hazard, or time-to-event outcomes related to cancer treatment. | 无 KM 图 |
| Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China.J Clin LipidolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41500861无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41519141无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41520567无 PMCID | 2026-Feb | 0.90 | The record is from a Phase III randomized trial (SHAPE) in oncology with human patients and time-to-event endpoints (RFS, OS) and original results (HR, 3-year rates). However, the intervention is surgical (simple vs radical hysterectomy), not a drug-containing intervention. Therefore, it does not meet the core inclusion criterion of a drug-containing intervention. | 无 KM 图 |
| Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Leukemia疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。 | PMID 41526614PMC12875879 | 2026-Feb | 0.45 | The record is an exploratory analysis of a Phase III randomized trial (IMerge) in oncology with a drug intervention. It is not eligible because it does not present a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) as a formal result; instead, it presents secondary biomarker and response-duration correlations. The original primary trial result is referenced but not reported in this abstract. | 无 KM 图 |
| Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).Leukemia | PMID 41526617PMC12875868 | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Instructed increase in fear activation during exposure exercises does not enhance treatment effects of cognitive behavioral therapy for panic disorder and agoraphobia.Behav Res TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41539132无 PMCID | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41539318无 PMCID | 2026-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图。 | PMID 41540105PMC12920140 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model.CPT Pharmacometrics Syst Pharmacol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。 | PMID 41543367PMC12823306 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.Clin Drug Investig已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。 | PMID 41545648PMC12872691 | 2026-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |